Efficacy of aflibercept (EYLEA®) on inhibition of human VEGF in vitro

Our results reveal that aflibercept significantly lowers the amount of unbound VEGF as well as the proliferation rate of HUVEC. Moreover, in contrast to specifications given by the manufacturer, aflibercept retains its full inhibitory effect up to at least 120 h after transference from the original vial into the injection syringe.